COVID-19 Neutralizing Antibody Test Solution

At present, outbreaks of the India variant (B.1.617.2) have been confirmed in the United Kingdom, China, the United States, Africa and Pacific Rim countries. Studies have shown that it seems to spread more easily and lead to more serious diseases. Countries all over the world are actively carrying forward COVID-19 vaccination in order to achieve mass immunization as soon as possible. With the advent of the post-pandemic era, the vaccination rates in China and abroad are continuously increasing. As of May 2021, a number of COVID-19 vaccines have been approved for marketing in China, including inactivated virus vaccines, subunit vaccines and recombinant adenovirus expression vaccines. At present, the protective efficacy data results of all Chinese COVID-19 vaccines approved for conditional marketing met the relevant technical standards of the World Health Organization and relevant national technical standards. As of June 16, 2021, a total of 2.13 billion doses of COVID-19 vaccines have been injected, with 27.3 doses per 100 people; 900 million doses of COVID-19 vaccines have been injected in China, with 62.82 doses per 100 people. The effect of COVID-19 vaccination and evaluation of effects have become the focus of public attention. NextSARS-CoV-2, its vaccines and neutralizing antibodies are introduced:

New launching!! Double-ended UDI UMI Adapter

An indispensable tool for low-frequency tumor genetic mutation detection. Double-ended UDI UMI Adapter

New Product Launching | Blood RNA-Seq "New Partner" is online!

New Product Launching | Blood RNA-Seq "New Partner" is online! Background Information As a medium for receiving, transmitting and responding to numerous biological signals, blood is involved in the metabolism, monitoring, maintenance of metabolism and immune function of almost all cells, tissues and organs. It is an easy-to-obtain clinical sample and it plays a vital role in the research of blood diseases, immunity, cancer, endocrine and other aspects. The rRNA content in total RNA of peripheral blood is more than 90%, and Globin mRNA accounts for about 70% of mRNA. These RNA genes can provide less effective information. The direct use of blood for sequencing not only produces a lot of worthless data, but also affects the detection of low abundance mRNA. Therefore, the effective removal of rRNA and Globin mRNA is the first important step for RNA library construction.  Product Description Ribo-off Globin & rRNA Depletion Kit (Human/Mouse/Rat) (N408) is for Blood Total RNA samples, through the steps of the hybridization of Globin mRNA and rRNA with probe, RNase H depletion, DNase I depletion and other steps, finally they are removed from Total RNA, and other mRNAs and non-coding RNAs are retained, which can be used for the analysis of non-coding RNAs such as LncRNA. Applicable sample types are abundant, compatible with low starting amount (0.01-1 μg) and low-quality samples. It can efficiently remove rRNA and Globin mRNA, and significantly improve the effective data information in sequencing data and the detection rate of low-abundance samples. Principle of the Experiment Figure 1. Schematic diagram of the removal of Globin mRNA and rRNA  Performance Show (1)The starting amount should be as low as 10 ng Set different initial input levels, use N408 to remove rRNA and Globin mRNA, and build and sequence the removed products to obtain high-quality Clean Reads. Compared to the number of Reads without the removal of rRNA genes and Globin mRNA genes and after using other companies’ products to remove rRNA genes and Globin mRNA genes, the results show that with different starting amounts (0.01-1μg), N408 can efficiently remove the target RNA. Figure 2. Removal effect of Globin mRNA and rRNA with different starting amounts (2) Removing rRNA and Globin mRNA from different types of samples and using the comparison software (BWA) to compare the sequencing data to the rRNA Sequencing database of their respective species, the results show that N408 can efficiently remove target RNA for samples of different species.  Figure 3. Globin mRNA and rRNA removal in different species (2)Efficient removal of low-quality samples Removing rRNA and Globin mRNA from samples with different RIN values, and performing library construction and sequencing on the removed products to obtain the number of Reads before and after using our company to remove the Globin mRNA genes and rRNA genes, and using other companies’ products to remove the Globin mRNA genes and rRNA genes, the results show that samples with different RIN values ​​can be removed efficiently by N408 Target RNA.  Figure 4. Globin mRNA and rRNA removal effect of samples with different RIN values Remove rRNA and Globin mRNA from samples with different starting amounts (0.01-1 μg) and different species, and use the new product - VAHTS® Universal V8 RNA-seq Library Prep Kit for Illumina (#NR605) for transcriptome library construction. Based on the comparison result of HISAT2, we use stringtie to complete the quantitative analysis of gene expression and count the number of gene detections. The results show that different starting amounts (0.01-1 μg) and samples of different species can guarantee a rich number of gene detections. Different Starting Amount (Human)                       Different species (100 ng) Figure 5. The number of genes detected in samples of different starting amounts and different species      Product Show               

Observation to Vazyme by Vice-chairman of National People's Congress

The observation is an important part of the annual key investigation of the Chinese Peasants and Workers Democratic Party and is considerably important in promoting scientific and technological development and innovation in China.

Cross Regional Sales Warning

Recently, some distributors of us Nanjing Vazyme Medical Technology Co.. Ltd.have salc-rclated activitics of our product 201 9-nCoV IgG/]gM Detcction Kit (Colloidal Gold-Based) in non-authorized area. This kind of activity has already affccted our brand image seriously and has violated the legal rights of Vazyme's other distributors.

Solemn Statement

Malaysia found pirated products, Vazyme hereby declares: The kits provided in Malaysia are 50 servings,and have the formal corresponding product delivery information (including production batch number and other information)

The products on this website may not be sold in all countries or regions. Please contact Vazyme or your local distributor for further information.


Address: Floor 1-3, Building C2, Red Maple Technology Industrial Park, Kechuang Road Economy & Technology Development Zone, Nanjing, China.

Copyright 2015 Vazyme Biotech Co.,Ltd All rights reserved  苏ICP备12014779号-1  Power by: www.300.cn nanjing.300.cn